The Food and Drug Administration says a breast cancer drug from Roche works to treat the disease in its early stages.
The agency gave the drug, Perjeta, a positive review, meaning it could become the first pharmaceutical option for treating the cancer's earliest stages. In online documents, the FDA said women who took Perjeta had significantly less tumors than women who took other drug combinations. The drug was issued prior to surgery to remove the tumors.
Scientists with the FDA are recommending an accelerated approval for the drug, a step that is generally reserved for groundbreaking treatments for fatal diseases.
Although Perjeta was approved last year for aggressive breast cancer that had already spread to different parts of the body, Roche is now asking for approval to use the drug during the disease's early stages.
All content © Copyright 2000 - 2014 WorldNow and WREX. All Rights Reserved.
Persons with disabilities who need assistance with issues relating to the content of this station's public inspection file should contact Administrative Assistant Trista Truesdale at (815) 335-7856. Questions or concerns relating to the accessibility of the FCC's online public file system should be directed to the FCC at 888-225-5322, at 888-835-5322 (TTY) or at email@example.com.